Epirubicin
Carcinoma, Ductal
Carisma Therapeutics IncPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Carcinoma, Ductal cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Survivin Peptide Vaccine University of Pennsylvania | Phase 1 | CC |
Htert University of Pennsylvania | Phase 1 | CC |
Pembrolizumab Carisma Therapeutics Inc | Phase 1 | CC |
Cyclophosphamide Carisma Therapeutics Inc | Phase 1 | CC |
ct-0508 Carisma Therapeutics Inc | Phase 1 | CC |
Same molecule, other indications
Epirubicin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →